GLP-1 REceptor Agonists and Real World EvIdeNce
Launched by UNIVERSITY OF PADOVA · May 20, 2019
Trial Information
Current as of April 25, 2025
Unknown status
Keywords
ClinConnect Summary
Introduction. Glucagon-like peptide-1 receptor agonists (GLP-1RA) are prioritized as a second-line therapy for the treatment of type 2 diabetes (T2D), especially in patients with a history of cardiovascular disease (CVD) or when there is a need to avoid weight gain and hypoglycemia. Randomized controlled trials (RCTs) have shown that addition of GLP-1RA is more effective in reducing HbA1c than addition of basal insulin (BI) in patients with uncontrolled T2D on oral therapy. GLP-1RA are associated with a low risk of hypoglycaemia and are provided with extra-glycemic effects, including reduct...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Type 2 diabetes
- • Diabetes duration of at least 1 year
- • Initiated on a GLP-1RA during the data collection period
- Exclusion Criteria:
- • Type 1 diabetes
- • Previous therapy with a GLP-1RA before the data collection period
About University Of Padova
The University of Padova, a prestigious research institution in Italy, is dedicated to advancing medical science through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration and cutting-edge research, the university fosters an environment conducive to the development of novel therapies and treatment modalities. Its commitment to ethical standards, patient safety, and scientific rigor ensures that all clinical trials are conducted with the highest level of integrity. Through these initiatives, the University of Padova aims to contribute significantly to the global medical community and improve health outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Padova, , Italy
Cittadella, Padova, Italy
Monselice, Padova, Italy
Pieve Di Soligo, Treviso, Italy
Padova, , Italy
Treviso, , Italy
Patients applied
Trial Officials
Gian Paolo Fadini, MD PhD
Study Chair
University of Padova
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials